Table 1.
Patient demographics per histology type (all stages, N = 53,561).
| Characteristics |
HGSOC |
OCCC |
MOC |
LGSOC |
P-value |
|---|---|---|---|---|---|
| Number | n = 38,199 | n = 5780 | n = 7561 | n = 2021 | |
| Age | 62.7 (±12.3) | 56.7 (±11.9) | 55.9 (±16.7) | 55.8 (±13.5) | <0.001 |
| <30 | 165 (0.4%) | 26 (0.4%) | 520 (6.9%) | 106 (5.2%) | |
| 30–39 | 926 (2.4%) | 330 (5.7%) | 791 (10.5%) | 221 (10.9%) | |
| 40–49 | 4709 (12.3%) | 1272 (22.0%) | 1301 (17.2%) | 394 (19.5%) | |
| 50–59 | 9434 (24.7%) | 1960 (33.9%) | 1815 (24.0%) | 453 (22.4%) | |
| 60–69 | 11,039 (28.9%) | 1345 (23.3%) | 1382 (18.3%) | 417 (20.6%) | |
| 70–79 | 8577 (22.5%) | 620 (10.7%) | 1128 (14.9%) | 290 (14.3%) | |
| ≥80 | 3349 (8.8%) | 227 (3.9%) | 624 (8.3%) | 140 (6.9%) | |
| Year | <0.001 | ||||
| 1988–1993 | 3360 (8.8%) | 487 (8.4%) | 1173 (15.5%) | 289 (14.3%) | |
| 1994–1999 | 4808 (12.6%) | 664 (11.5%) | 1229 (16.3%) | 344 (17.0%) | |
| 2000–2005 | 10,112 (26.5%) | 1470 (25.4%) | 1996 (26.4%) | 599 (29.6%) | |
| 2006–2011 | 10,748 (28.1%) | 1630 (28.2%) | 1673 (22.1%) | 456 (22.6%) | |
| 2012–2016 | 9171 (24.0%) | 1529 (26.5%) | 1490 (19.7%) | 333 (16.5%) | |
| Race/ethnicity | <0.001 | ||||
| White | 29,608 (77.5%) | 4044 (70.0%) | 5297 (70.1%) | 1548 (76.6%) | |
| Black | 2353 (6.2%) | 228 (3.9%) | 614 (8.1%) | 138 (6.8%) | |
| Hispanic | 3542 (9.3%) | 518 (9.0%) | 863 (11.4%) | 228 (11.3%) | |
| Asian | 2219 (5.8%) | 896 (15.5%) | 644 (8.5%) | 82 (4.1%) | |
| Othersa | 477 (1.2%) | 94 (1.6%) | 143 (1.9%) | 25 (1.2%) | |
| Registry | <0.001 | ||||
| West | 21,520 (56.3%) | 3451 (59.7%) | 4049 (53.6%) | 1058 (52.4%) | |
| Central | 7223 (18.9%) | 967 (16.7%) | 1704(22.5%) | 419 (20.7%) | |
| East | 9456 (24.8%) | 1362 (23.6%) | 1808 (23.9%) | 544 (26.9%) | |
| Marital status | <0.001 | ||||
| Single | 5130 (13.4%) | 1345 (23.3%) | 1690 (22.4%) | 397 (19.6%) | |
| Married | 21,008 (55.0%) | 3149 (54.5%) | 3625 (47.9%) | 1099 (54.4%) | |
| Others | 10,915 (28.6%) | 1091 (18.9%) | 1987 (26.3%) | 478 (23.7%) | |
| Unknown | 1146 (3.0%) | 195 (3.4%) | 259 (3.4%) | 47 (2.3%) | |
| Stage | <0.001 | ||||
| I | 3269 (8.6%) | 3293 (57.0%) | 4501 (59.5%) | 687 (34.0%) | |
| II | 3056 (8.0%) | 645 (11.2%) | 492 (6.5%) | 219 (10.8%) | |
| III | 20,916 (54.8%) | 1237 (21.4%) | 1395 (18.4%) | 861 (42.6%) | |
| IV | 10,958 (28.7%) | 605 (10.5%) | 1173 (15.5%) | 254 (12.6%) | |
| Nodal metastasisa | <0.001 | ||||
| No | 9114 (51.0%) | 3228 (84.6%) | 3255 (90.7%) | 713 (68.6%) | |
| Yes | 8733 (48.9%) | 603 (15.3%) | 330 (9.2%) | 325 (31.3%) | |
| Unknown | 19 (0.1%) | 5 (0.1%) | 2 (0.1%) | 1 (0.1%) | |
| LNR | 50.0 (IQR 18.2–100) | 33.3 (IQR 12.5–69.0) | 33.3 (IQR 12.5–100) | 28.6 (IQR 14.3–66.7) | <0.001 |
| Tumor size (cm) | <0.001 | ||||
| <5 | 6154 (16.1%) | 723 (12.5%) | 932 (12.3%) | 386 (19.1%) | |
| 5–9.9 | 8584 (22.5%) | 1064 (18.4%) | 703 (9.3%) | 406 (20.1%) | |
| 10–14.9 | 5487 (14.4%) | 1220 (21.1%) | 821 (10.9%) | 228 (11.3%) | |
| ≥15 | 3195 (8.4%) | 1380 (23.9%) | 2145 (28.4%) | 203 (10.0%) | |
| Unknown | 14,779 (38.7%) | 1393 (24.1%) | 2960 (39.1%) | 798 (39.5%) | |
| Oophorectomy | <0.001 | ||||
| No | 1718 (4.5%) | 167 (2.9%) | 762 (10.1%) | 65 (3.2%) | |
| Yes | 36,227 (94.8%) | 5592 (96.7%) | 6731 (89.0%) | 1945 (96.2%) | |
| NOSa | 254 (0.7%) | 21 (0.4%) | 68 (0.9%) | 11 (0.5%) | |
| Hysterectomy | <0.001 | ||||
| No | 5271 (13.8%) | 702 (12.1%) | 2302 (30.4%) | 383 (19.0%) | |
| Yes | 29,708 (77.8%) | 4813 (83.3%) | 4745 (62.8%) | 1463 (72.4%) | |
| Unknown | 3220 (8.4%) | 265 (4.6%) | 514 (6.8%) | 175 (8.7%) | |
| Lymphadenectomy | <0.001 | ||||
| No | 20,112 (52.7%) | 1822 (31.5%) | 3910 (51.7%) | 971 (48.0%) | |
| Yes | 17,866 (46.8%) | 3936 (68.1%) | 3587 (47.4%) | 1039 (51.4%) | |
| Unknown | 221 (0.6%) | 22 (0.4%) | 64 (0.8%) | 11 (0.5%) | |
| Sampled nodesb | 9 (IQR 3–19) | 12 (IQR 5–21) | 10 (IQR 4–18) | 10 (IQR 4–19) | <0.001 |
| Chemotherapy | <0.001 | ||||
| No | 7349 (19.2%) | 1590 (27.5%) | 4388 (58.0%) | 835 (41.3%) | |
| Yes | 30,850 (80.8%) | 4190 (72.5%) | 3173 (42.0%) | 1186 (58.7%) |
Number (percentage per column), mean (±standard deviation), or median (interquartile range) is shown. One-way ANOVA test, Kruskal-Wallis H test, or chi-square test for P-values. Abbreviations: IQR, interquartile range; NOS, not otherwise specified; HGSOC, high-grade serous ovarian carcinoma; OCCC, ovarian clear cell carcinoma; MOC, mucinous ovarian carcinoma; and LGSOC, low-grade serous ovarian carcinoma.
a
Including unknown.
b
Among staged cases